Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study.
about
Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodesOncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future PerspectivesInto the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapyThe efficacy of combination therapy with oncolytic herpes simplex virus HF10 and dacarbazine in a mouse melanoma model.Novel melanoma therapy.Intratumoral Delivery of Immunotherapy-Act Locally, Think Globally.Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy.Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases.Imaging Manifestations of Pseudoprogression in Metastatic Melanoma Nodes Injected with Talimogene Laherparepvec: Initial Experience.Designing and building oncolytic viruses.Synthetic immune niches for cancer immunotherapy.Talimogene Laherparepvec: First in Class Oncolytic Virotherapy.A novel immunization strategy using cytokine/chemokines induces new effective systemic immune responses, and frequent complete regressions of human metastatic melanoma.Tumor-Associated Macrophages in Oncolytic Virotherapy: Friend or Foe?HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses
P2860
Q28077949-C7C9F383-4312-4F0B-B670-92D2760C57AAQ33679505-BE30882C-C5C0-4ABF-9505-1C7B2C0515F9Q37267785-DEFC384C-88A3-4323-B900-313F2EB82C5CQ38598702-EA6D5628-90B0-4711-BE41-2D4832AE012FQ38923489-27F29F67-ABA7-408F-A293-9112E5392E3FQ39043844-F05D50DE-099A-419E-BBFA-FEF55265C816Q40200213-157E52E4-E8DE-4F8F-9E6A-D3ECD2B3E61EQ40227808-BBBC60BC-BFC8-4075-8253-4CDEC631B4A7Q40233749-56E30B6F-6F10-4FAC-A4B0-16BD4CBE77ACQ47547386-ADCD7698-E585-46F5-956C-45B2003A6BE6Q47739711-7502CB1C-E844-41A4-B760-2200775B2163Q50116255-9E50E5E2-5A0F-40C6-B4D8-AF69944DBABFQ50545431-8BE3A520-B81F-4776-8BD4-13C1B0C28E1CQ52769260-66AA7C47-1F00-4800-9787-6EF001AD6724Q56378150-F897A852-3CDB-4232-A28A-8BA2A7F07A1B
P2860
Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Systemic versus local response ...... -institutional phase II study.
@en
Systemic versus local response ...... -institutional phase II study.
@nl
type
label
Systemic versus local response ...... -institutional phase II study.
@en
Systemic versus local response ...... -institutional phase II study.
@nl
prefLabel
Systemic versus local response ...... -institutional phase II study.
@en
Systemic versus local response ...... -institutional phase II study.
@nl
P2093
P2860
P1476
Systemic versus local response ...... i-institutional phase II study
@en
P2093
Eric Whitman
John Glaspy
John Nemunaitis
Kevin Harrington
Michael Wolf
Neil N Senzer
Rene Gonzalez
Thomas Amatruda
P2860
P2888
P356
10.1186/S40425-016-0116-2
P577
2016-03-15T00:00:00Z
P6179
1045802054